New Nature Medicine
The longest randomized trial assessment—4 years— of semaglutide (Wegovy) in participants without diabetes
nature.com/articles/s4159…
Sustained weight loss, no new side effects noted

Onion rava masala dosa

👌🏽👌🏽

Peppino’s Dosa in Waltham, MA

Good news re the #BIOSECURE act, the House just published new text that now includes a grandfathering for existing contracts/products until Jan 1, 2032, giving the industry ~8 years to switch manufacturing partners and services. There were huge concerns that this process would…

We often get asked:

We have such great meds for cholesterol already. What’s the unmet need?

Challenge: time on therapy is cut short by so many barriers in our system

👇🏽highlights one reason for short time on therapy and its adverse consequences.

Amitabh Chandra

No matter how grown up they get, nothing better than ice cream with your little girl. ❤️

⁦Van Leeuwen Ice Cream⁩

Veg thali

Amma’s

👌🏽😋

Obesity causes sleep apnea

Treat underlying cause—> reduce sleep apnea

Yet another win for GLP-1 receptor agonists

20% weight loss led to dramatic reduction in number of episodes of breathing stoppage at night.
statnews.com/2024/04/17/eli…

Atherosclerosis evaluation and cardiovascular risk estimation using coronary computed tomography angiography. A State-of-the-Art Review just published in #EHJ
European Society of Cardiology European Society of Cardiology Journals #CardioTwitter #atherosclerosis #CCTA Dr. Deepak L. Bhatt Nick Nurmohamed

academic.oup.com/eurheartj/adva…

This is new

Puppies at #ACC24 !

🐶

American College of Cardiology

Maybe the eternal search for an effective HFpEF med is finally over?

Amazing!

Another win for GLP-1 receptor agonists,

now in heart failure with preserved ejection fraction (HFpEF)

Honored to celebrate this dedicated, hard-working group who represent our program at the highest level inside and outside the classroom on #NationalStudentAthleteDay 👊

#FightOnPenn 🔴🔵⚽️

4-weekly infusions of CSL ApoA1 infusions shows no statistical difference in outcomes vs. placebo in reducing 90-day CV events, AEGIS-II trial shows. Download slides from AEGIS-II here: rb.gy/7mi21c

Quite the morning here in New England and our house 💨